Rising Insulin Resistance Score Signals Higher Gout Risk, Large Chinese Cohort Finds

A simple calculation from two routine blood tests may reveal who is quietly drifting toward one of the fastest-growing metabolic conditions of our time. In a study of more than 21,000 adults tracked across three consecutive annual health examinations in Chengdu, China, researchers found that a one-year rise in the triglyceride-glucose index, a widely used proxy for insulin resistance, was associated with a measurably higher risk of developing hyperuricemia, the elevated serum urate state that precedes gout. The work, published in BMC Endocrine Disorders, offers one of the clearest longitudinal pictures yet of how dynamic shifts in metabolic health translate into uric acid trouble downstream.

The triglyceride-glucose index, usually abbreviated TyG, is computed as the natural logarithm of fasting triglycerides in milligrams per deciliter multiplied by fasting glucose, divided by two. Because both ingredients come from standard lipid and glucose panels, the index costs essentially nothing to calculate and has become a popular surrogate for insulin resistance in large epidemiological studies, where direct clamp-based measurements of insulin sensitivity are impractical. Prior cross-sectional work had already linked higher TyG values to higher urate levels, but those snapshots could not disentangle whether a person’s trajectory, rather than their standing, carried the risk signal.

That distinction matters because longitudinal studies of repeated measurements face a subtle statistical trap. If you measure an exposure, such as the TyG index, at the same visit at which you also confirm the outcome, such as hyperuricemia, the two overlap in time and the analysis can become circular. The research team, led by LingYi Feng and Ke Li of the Department of Clinical Laboratory at The Third People’s Hospital of Chengdu, addressed this with a landmark cohort design, a technique borrowed from survival analysis in which participants must remain free of the outcome up to a fixed landmark time before their subsequent risk is assessed.

Concretely, the investigators drew on de-identified health-examination records from 2023 through 2025 at their tertiary hospital. Only adults who remained normouricemic through the 2024 landmark were eligible, ensuring that the exposure window, the change in TyG between the 2023 and 2024 examinations, strictly preceded the outcome window, the development of hyperuricemia in 2025. The prespecified primary analysis then modeled that one-year TyG change jointly with baseline TyG, age, and sex, while also adjusting for the most recent pre-outcome values of serum urate and estimated glomerular filtration rate, the standard measure of kidney function, both taken from 2024. Because the kidneys excrete the bulk of uric acid, renal function is a critical confounder in any urate study, and using the 2024 values meant the model controlled for kidney status as close to the outcome as the data allowed.

The statistical machinery was modified Poisson regression with robust variance, an approach that estimates risk ratios directly rather than odds ratios, which can overstate effects in common outcomes like hyperuricemia. Among the 21,188 participants who met the eligibility criteria, 1,171, or 5.5 percent, developed hyperuricemia during 2025. In the primary model, each one-standard-deviation greater increase in the TyG index over the 2023-to-2024 year was associated with a 12 percent higher risk of subsequent hyperuricemia, with a risk ratio of 1.120 and a 95 percent confidence interval of 1.061 to 1.181. The confidence interval sits comfortably above 1.0, indicating a statistically robust association.

To test whether the result depended on the choice of adjustment variables, the team ran a complementary model that instead used 2023 serum urate and eGFR, the baseline-covariate version. The estimate barely moved, coming in at a risk ratio of 1.139 with a confidence interval of 1.080 to 1.201. This kind of sensitivity check is important in observational epidemiology, where results can hinge on modeling decisions. The consistency across both specifications suggests the association between rising insulin resistance and incident hyperuricemia is not an artifact of how kidney function or urate levels were anchored in the models.

Yet the study is equally notable for what it did not find. When the researchers asked whether adding one-year TyG change improved the model’s ability to discriminate who would and would not develop hyperuricemia, the gain was almost negligible: the C-statistic, a measure of predictive accuracy where 0.5 represents coin-flip performance and 1.0 represents perfection, rose only from 0.801 to 0.803. In plain terms, the most recent serum urate measurement and kidney function already carried nearly all the predictive information, and knowing how much a person’s TyG index had climbed added almost nothing to individual-level forecasting. The authors are explicit on this point, cautioning that the findings should be interpreted as observational associations rather than evidence of clinical predictive utility or causality.

That honesty is refreshing in a field where novel biomarker studies often overstate their practical implications. The biology linking insulin resistance to urate elevation is plausible and increasingly well mapped. Insulin resistance drives compensatory hyperinsulinemia, which stimulates renal sodium reabsorption and, through shared transporters in the proximal tubule, reduces urinary uric acid excretion. Elevated triglycerides and free fatty acids can also accelerate purine synthesis in the liver, increasing urate production from both ends of the balance. Transporter proteins such as URAT1 and ABCG2, which the study’s abbreviation list flags, sit at the molecular crossroads of this pathway, shuttling urate across renal and intestinal epithelia in ways that are sensitive to the metabolic milieu.

The study’s strengths lie in its scale, its clean temporal separation of exposure and outcome, and its reproducibility posture. The authors released Python analysis scripts, a data dictionary, locked machine-readable expected results, and figure-reproduction files as supplementary material, an unusually transparent package for a clinical epidemiology paper. The analysis followed STROBE reporting guidelines for observational studies, and the protocol, including the prespecified primary model, was defined before the analysis. Ethics approval came from the hospital’s medical ethics committee, with the consent requirement waived because only de-identified routine examination data were used.

Limitations remain, as they always do in single-center retrospective work. All participants came from one tertiary hospital in Chengdu, so the findings may not generalize to other populations or health systems. Health-examination cohorts also tend to skew toward people engaged enough with health care to show up annually, which can underrepresent the most metabolically vulnerable. Hyperuricemia was defined by serum urate thresholds rather than by clinical gout diagnoses, and the one-year measurement interval cannot capture shorter-term fluctuations in diet, weight, or medication use that might influence both TyG and urate. Residual confounding by unmeasured factors, from alcohol intake to diuretic prescriptions, cannot be excluded.

For readers wondering what to take away, the practical message is modest but meaningful. A rising TyG index over a year, visible in ordinary bloodwork, tracks with a modestly elevated chance of crossing the hyperuricemia threshold the following year, even after accounting for where you started and how your kidneys are doing. It is a signal worth watching in population health and in clinical conversations about metabolic trajectory, but it is not yet a tool that will refine anyone’s personal risk prediction. The authors’ own framing sets the right expectation: this is an observational association, a well-executed one, that adds a longitudinal brick to the growing wall of evidence connecting insulin resistance and uric acid metabolism, while leaving the questions of causation and clinical utility for future interventional and multi-center studies to answer.

Subject of Research: Association between one-year change in the triglyceride-glucose index and incident hyperuricemia in adults

Article Title: One-year change in the triglyceride-glucose index and subsequent incident hyperuricemia: a retrospective landmark cohort study

Article References: One-year change in the triglyceride-glucose index and subsequent incident hyperuricemia: a retrospective landmark cohort study. (n.d.). https://doi.org/10.1186/s12902-026-02663-7

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02663-7

Keywords: triglyceride-glucose index, hyperuricemia, insulin resistance, serum urate, cohort study, landmark analysis, gout, kidney function, epidemiology, metabolic health, modified Poisson regression, BMC Endocrine Disorders